Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com
Rod A. Humerickhouse, MD, PhD, Group Project Leader, Oncology Development, AbbVie, discusses Testing For Minimal Residual Disease In CLL. At The 60th ASH Annual Meeting on Dec 1, 2018. http://obroncology.com